De novo entecavir+adefovir dipivoxil+lamivudine triple-resistance mutations resulting from sequential therapy with adefovir dipivoxil, and lamivudine.
PMID: 27079793
2016
Annals of clinical microbiology and antimicrobials
Result: Notably, this study also included two patients with de novo ETV resistance mutations at rtT184 A and rtM250 L after LAM+ADV treatment, but no further clonal analyses were conducted in these patients.
Analysis of HBV genotype, drug resistant mutations, and pre-core/basal core promoter mutations in Korean patients with acute hepatitis B.
Result: Nevertheless, LMV-associated mutation rtM204V/I and rtL180M, LdT-associated mutation rtM204I, and ETV-associated mutations rtT184A/I/S, rtS202G and rtM250L didn't differ significantly between genotype B and C (P > 0.05).
Drug-resistance associated mutations in polymerase (p) gene of hepatitis B virus isolated from malaysian HBV carriers.
Abstract: A number of significant drug resistant mutations were found in five patients including S202I, N236T, M250L, L180M/V, M204I, A181T, T184G,
Table: M250L
Discussion: Adefovir resistance was caused by N236T and /or A181V amino acid substitution, whereas entecavir resistance resulted from HBV reverse transcriptase substitutions at positions T184, S202, or M250L which emerge in the presence of lamivudine resistance substitutions M204I/V and L180M.
Mutations in HBV DNA polymerase associated with nucleos(t)ide resistance are rare in treatment-naive patients.
PMID: 24342744
2014
Clinical gastroenterology and hepatology
Abstract: Mutations in HBV DNA polymerase were found in 2 patients (1%), rtI233V (n = 1) and rtM250M/L (n = 1).
Profile of hepatitis B virus resistance mutations against nucleoside/nucleotide analogue treatment in Chinese patients with chronic hepatitis B.
Introduction: According to previously studies, the patterns of genotypic resistance in the HBV polymerase can be categorized into five specific evolutionary pathways, including L-nucleoside pathway (rtM204I [or V or I/V]), the acyclic phosphonate pathway (rtN236T), the shared pathway (rtA181T [or V or T/V]) of both L-nucleoside and acyclic phosphonate, ETV resistance pathway (rtL180M+rtM204V with one of either rtT184, S202 or M250 residue changes) and multidrug resistance pathways (rtA181T+
Quasispecies and pre-existing drug-resistant mutations of hepatitis B virus in patients with chronic hepatitis B.
Discussion: In another large-scale study, three out of 255 (1.2%) treatment-naive patients had the rtM250L/V mutation typical of ETV resistance.
Large-scale survey of naturally occurring HBV polymerase mutations associated with anti-HBV drug resistance in untreated patients with chronic hepatitis B.
Abstract: Four patients had the rtI233V mutation that may reduce sensitivity to adefovir, and three patients had the rtM250L/V mutation typical of entecavir resistance.
Genotypic resistance profile of hepatitis B virus (HBV) in a large cohort of nucleos(t)ide analogue-experienced Chinese patients with chronic HBV infection.
Method: The rtT184A/C/F/G/I/L/M/S, rtS202C/G/I and rtM250I/L/V were defined as the signature ETV-resistant mutations (ETV-R) if concomitant with rtM204I/V.
Table: M250L
[Detection of HBV resistant mutations related to lamivudine, adefovir and entecavir by reverse hybridization technique].
Abstract: To detect non-synonymous amino acid substitutions associated with lamivudine, adefovir and entecavir, 26 specific oligonucleotide probes covering ten different codon positions, I169T, V173L/G, L180M, A181T/V, T184G, S202I/G, M204V/I, Q215S, N236T and M250V/I/L were synthesized and immobilized on nylon membranes charged positively.
HBV mutation literature information.
PMID: 
2016
Annals of clinical microbiology and antimicrobials
Browser Board
Co-occurred Entities
Filtrator
ViMRT